Logo

BMS' Opdivo (nivolumab) + Yervoy (ipilimumab) Receive EC's Approval for dMMR or MSI-H mCRC After Prior Chemotherapy

Share this

BMS' Opdivo (nivolumab) + Yervoy (ipilimumab) Receive EC's Approval for dMMR or MSI-H mCRC After Prior Chemotherapy

Shots:

  • The approval is based on P-II CheckMate -142 study evaluating Opdivo + Yervoy in patients with dMMR or MSI-H mCRC whose disease had progressed during or after prior treatment with CT
  • Results: @ minimum follow-up of 46.9mos. improvement in ORR (64.7%) with 12.6% patients achieve a CR- m-DoR was not reached & safety profile was consistent with previous studies of combination in other tumor types
  • The combination marks the 1st approved dual immunotherapy regimen for any GI tumor & also approved for NSCLC & RCC in the EU. The marketing authorization approve the use of combination in all EU member states- Norway- Iceland & Liechtenstein

  Ref: BMS | Image: BMS

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions